SS Innovations Reports Strong Preliminary 2025 Revenue Growth and Anticipates Key Regulatory Milestones
Summary
SS Innovations International announced preliminary unaudited revenue for Q4 and full year 2025, showing significant growth in revenue and surgical robotic system installations, alongside anticipated FDA and CE Mark approvals in the first half of 2026.
Key Events
-
Preliminary Full Year 2025 Revenue
Reported approximately $43.0 million, a 108% increase from $20.6 million in 2024.
-
Preliminary Q4 2025 Revenue
Announced approximately $15.0 million, an 85% increase from $8.1 million in Q4 2024.
-
SSi Mantra Installations
Cumulative installed base reached 168 systems by December 31, 2025, up 158% year-over-year, with 103 installations in 2025.
-
Anticipated Regulatory Milestones
Expects U.S. FDA 510(k) premarket notification review and European Union CE marking certification for the SSi Mantra in the first half of 2026.
Analysis
The company's preliminary results indicate robust operational momentum, with full-year 2025 revenue more than doubling compared to the previous year. This strong performance, driven by increased installations of its SSi Mantra surgical robotic system, underscores the growing adoption of its cost-effective technology. The anticipated regulatory clearances from the U.S. FDA and for the European CE Mark in the first half of 2026 are critical catalysts, paving the way for significant market expansion into major global healthcare markets. Investors should monitor the final audited results and the progress of these regulatory approvals, which could substantially impact the company's future growth trajectory.
At the time of this filing, SSII was trading at $6.18 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $3.02 to $22.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.